Hemophilia A News and Research

RSS

Baxter fourth quarter net income declines 26% to $423 million

Baxter International Inc. today announced its financial results for the fourth quarter of 2010, and provided its financial outlook for the first quarter and full-year 2011.

From Baxter International Inc. 27 Jan 2011

PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology

PROLOR Biotech, Inc., today announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd. for novel technology utilized in the development of long-acting therapeutic peptides and small molecules, termed Reversible PEGylation.

18 Jan 2011

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Sangamo BioSciences, Inc. announced today that the company completed enrollment of its Phase 2b double-blind, placebo-controlled clinical trial (SB-509-901) in subjects with diabetic neuropathy (DN). The company expects to have efficacy data from this study in the second half of 2011. The company also plans to present the first human clinical data from its Phase 1 trials of SB-728-T in HIV/AIDS in the first quarter of 2011.

10 Jan 2011

Catalyst receives $4.0M milestone payment from Pfizer under hemophilia Factor VIIa program

Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced the receipt of a $4.0 million milestone payment from Pfizer Inc. under the terms of the collaboration agreement for the development of improved recombinant human Factor VIIa variants for the treatment of hemophilia and other bleeding disorders.

17 Dec 2010

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

Octapharma USA researchers presented new stringent, objective criteria used in the evaluation of hemostatic efficacy in the treatment of von Willebrand disease and reported on their application of these criteria in clinical trials during the recently completed National Hemophilia Foundation Annual Meeting.

9 Dec 2010

rVWF safe in patients with type 3 and severe type 1 von Willebrand disease, suggests interim study data

Recombinant von Willebrand factor (rVWF) may be safe and well tolerated in patients with type 3 and severe type 1 von Willebrand disease, according to interim data from a Phase 1 multicenter, international clinical study presented today at the 52nd Annual Meeting of the American Society of Hematology.

From Baxter International Inc. 7 Dec 2010

No evidence of toxicity in hemophilia B patients enrolled in gene therapy trial

Investigators report no evidence of toxicity in the four hemophilia B patients enrolled to date in a gene therapy trial using a vector under development at St. Jude Children's Research Hospital and UCL (University College London) to correct the inherited bleeding disorder.

7 Dec 2010

First patient dosed with rFVIIIFc in A-LONG trial

Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient has been dosed with the companies' long-lasting recombinant Factor VIII Fc fusion protein (rFVIIIFc) in a global registrational clinical trial. The study, called A-LONG, is an open-label, multicenter, Phase 2/3 study designed to evaluate the safety, pharmacokinetics and efficacy of rFVIIIFc in previously-treated hemophilia A patients.

6 Dec 2010

CSL Behring launches next generation HeliTrax System for Apple's devices

CSL Behring announced today the availability of the next generation HeliTrax System as part of a specially designed software platform for Apple's iPhone, iPod touch, or iPad devices. This enhanced system is designed to improve therapy management for people with hemophilia A who use CSL Behring's recombinant factor VIII (rFVIII).

2 Dec 2010

Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix

Baxter International Inc. announced today that it has entered into a definitive agreement to acquire all of the hemophilia-related assets of a privately-held biopharmaceutical company, Archemix, and entered into an exclusive license agreement for certain related intellectual property assets.

From Baxter International Inc. 19 Nov 2010

Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A

Ipsen announced today that its partner Inspiration Biopharmaceuticals, Inc. has initiated treatment of patients in the first of two phase III pivotal clinical studies of OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product, for the treatment of acquired hemophilia A, a rare, though potentially life-threatening bleeding disorder.

19 Nov 2010

Amsterdam 2010 third quarter total expense increases from EUR 4.4 million to EUR 4.7 million

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the third quarter of 2010.

18 Nov 2010

Science and precedent do not support biosimilar approach for plasma protein therapies

The current science and experience does not support the safety and efficaciousness of a biosimilar pathway for plasma protein therapies. At a public hearing last week, the Plasma Protein Therapeutics Association (PPTA) urged the United States Food and Drug Administration (FDA) to make patient safety its top priority by adopting a global approach in its evaluation of plasma protein therapies for the biosimilars process.

15 Nov 2010

NJIT expert to discuss history of sickle cell disease at NIH symposium

The history of sickle cell disease in the 20th century and its link to race is the focus of a Nov. 16, 2010 talk at a national symposium by NJIT Associate Professor Stephen Pemberton, PhD, an expert on the history of diseases. Pemberton will speak and join a panel discussion at the National Institutes of Health (NIH), Bethesda, 100th anniversary symposium commemorating the discovery of sickle cell disease by Chicago physician James B. Herrick.

11 Nov 2010

Inspiration receives two grants under QTDP program to advance development of IB1001, OBI-1 products

Inspiration Biopharmaceuticals, Inc. today announced the Company was awarded two grants, totaling $488,958, under the Qualifying Therapeutic Discovery Projects Grant Program (QTDP).

9 Nov 2010

Researchers investigate Human-cl rhFVIII factor for severe hemophilia A treatment

Octapharma AG, one of the largest human protein products manufacturers in the world, and Octapharma USA today announced that patients diagnosed with severe hemophilia A have started treatment in a multi-center study that is researching the use of the first recombinant Factor VIII (rFVIII) derived from a human cell line (Human-cl rhFVIII).

2 Nov 2010

Hemophiliacs, hepatitis and HIV: A magic cure gone wrong

The dark side of capitalism’s effect on the medical and pharmaceutical industries is chillingly exposed in Doctor Guilt? Benefits of Medical Treatment Compared with Hazards – A tradeoff (published by iUniverse), the provocative new nonfiction by Everett Winslow Lovrien, M.D.

28 Oct 2010

Octapharma initiates Human-cl rhFVIII clinical study for severe hemophilia A

Octapharma, one of the largest human protein products manufacturers in the world, today announced that patients diagnosed with severe hemophilia A have started treatment with the first recombinant Factor VIII derived from a human cell line (Human-cl rhFVIII). Researchers are investigating pharmacokinetics, efficacy, safety and immunogenicity of Human-cl rhFVIII for previously treated patients with severe hemophilia A.

28 Oct 2010

GTC 2010 third fiscal quarter net loss decreases to $4.5 million from $26.2 million

GTC Biotherapeutics, Inc. today reported its financial results for the third fiscal quarter ended September 30, 2010.

28 Oct 2010

Bayer launches unique fitness program for hemophilia A children

Bayer HealthCare is introducing a fitness program to help children ages 7-12 and young adults ages 13-16 with hemophilia A live active lives. "Living Fit! A Joint Effort" is a unique strength training, fitness and wellness program created to increase awareness of the importance of exercise and nutrition among this population and their caregivers.

27 Oct 2010

Hemophilia A News and Research

Baxter fourth quarter net income declines 26% to $423 million

PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Catalyst receives $4.0M milestone payment from Pfizer under hemophilia Factor VIIa program

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

rVWF safe in patients with type 3 and severe type 1 von Willebrand disease, suggests interim study data

No evidence of toxicity in hemophilia B patients enrolled in gene therapy trial

First patient dosed with rFVIIIFc in A-LONG trial

CSL Behring launches next generation HeliTrax System for Apple's devices

Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix

Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A

Amsterdam 2010 third quarter total expense increases from EUR 4.4 million to EUR 4.7 million

Science and precedent do not support biosimilar approach for plasma protein therapies

NJIT expert to discuss history of sickle cell disease at NIH symposium

Inspiration receives two grants under QTDP program to advance development of IB1001, OBI-1 products

Researchers investigate Human-cl rhFVIII factor for severe hemophilia A treatment

Hemophiliacs, hepatitis and HIV: A magic cure gone wrong

Octapharma initiates Human-cl rhFVIII clinical study for severe hemophilia A

GTC 2010 third fiscal quarter net loss decreases to $4.5 million from $26.2 million

Bayer launches unique fitness program for hemophilia A children

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News